The long-overlooked safety issue weighing on the FDA’s mind on day 1 of marathon gene therapy meeting
As the FDA closed out day 1 of its marathon gene therapy hearing, the agency gave an unusual glimpse into their conversations — and conflict …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
